iShares Core MSCI Europe ETF (ARCA: IEUR)

iShares Core MSCI Europe ETF (ARCA:IEUR), Quote.Headers.trade-ideas

iShares Core MSCI Europe ETF

Financial Services

Industrials

Healthcare

Consumer Cyclical

Consumer Defensive

Technology

Basic Materials

Energy

Communication Services

Utilities

Other

Real Estate

The fund generally will invest at least 90% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index which consists of securities from the following 15 developed market countries or regions: Austria, Belgium, Denmark, Finland, France, Germany, Ireland, Italy, the Netherlands, Norway, Portugal, Spain, Sweden, Switzerland and the United Kingdom.

Novo Nordisk As

Asml Holding Nv Common Stock Eur 0.09

Nestle Capital Corp.

Astrazeneca Plc

LVMH Moet Hennessy Louis Vuitton SE

Macro,Shot,Of,Computer,Monitor,With,World,Stock,Market,Chart

Asia

News

Emerging Markets

Eurozone

Futures

Commodities

Forex

Markets

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

US markets close higher following Fed&#39;s rate cut and positive economic data. Asian markets rise, European markets decline. Gold and oil prices up.

Asia Markets Advance, Europe Edges Lower And Gold Clocks New High At $2,630 – Global Markets Overview

US markets closed lower as Fed cuts interest rates by 50 basis points, first cut in 4 years. Asian and European markets rise, commodities mostly up.

Asia And Europe Up, Crude And Gold Gain Following Fed&#39;s Rate Cut - Global Markets Today While US Slept

Economic data boosts U.S. markets, S&amp;P 500 nearly flat. Japan&#39;s Nikkei 225 and Australia&#39;s S&amp;P/ASX 200 up, while China&#39;s Shanghai Composite gains.

Asia Mostly Up, Europe Mixed; Gold Gains As And Dollar Softens - Global Markets Today While US Slept

Boeing Says Reached Out To The Union To Give Them More Time And Offer Logistical Support Once They Decide To Vote

<p><strong>Las Vegas Sands Corp.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LVS#NYSE">LVS</a>) shares are trading higher by 6% to $44.65 Tuesday afternoon, propelled by the <strong>People&#8217;s Bank of China&#8217;s (PBoC)</strong> announcement of a broad monetary <a href="https://www.benzinga.com/markets/asia/24/09/41003814/chinese-stocks-jump-as-central-bank-unveils-major-stimulus-to-spur-economy-a-step-in-the-right-direc">stimulus package</a> aimed at revitalizing <strong>China&#8217;s</strong> slowing economy.</p>
<p>The PBoC&#8217;s unexpected measures, including significant cuts to the <strong>reserve requirement ratio (RRR)</strong> for banks and the seven-day repo rate, injected new optimism into the markets, particularly for companies with substantial exposure to the Chinese economy.</p>
<p><strong>Why This Matters:</strong> Las Vegas Sands, one of the world's largest casino operators, derives a significant portion of its revenue from its properties in Macau, a <strong>Special Administrative Region</strong> of China. </p>
<p>Macau's casinos, heavily reliant on Chinese tourism and consumer spending, have faced challenges over the past few years due to China&#8217;s slowing economic growth, regulatory crackdowns and travel restrictions stemming from the pandemic. </p>
<p><strong>Read Also: <a href="https://www.benzinga.com/government/24/09/41004045/whats-going-on-with-chinese-stocks-alibaba-nio-xpeng-li-auto-on-tuesday">What&#8217;s Going On With Chinese Stocks Alibaba, NIO, XPeng, Li Auto On Tuesday?</a></strong></p>
<p>The PBoC's move to cut the RRR by 50 basis points, releasing $140 billion of liquidity into the banking system, is particularly beneficial for businesses like Las Vegas Sands that rely on Chinese consumer spending. </p>
<p>By making it easier for Chinese consumers to access loans and credit, the monetary easing is expected to boost disposable income and discretionary spending, which are critical to the casino and entertainment sectors in Macau. </p>
<p><strong>What Else:</strong> The reduction in mortgage rates and other financial burdens is also seen as a direct relief to the property market, which also has ripple effects on consumer confidence and spending in other areas, including leisure and travel.</p>
<p>The seven-day repo rate cut of 20 basis points and the ongoing reductions in policy rates signal a broad easing of monetary conditions, which could lead to a rebound in domestic tourism and gaming revenues in Macau. </p>
<p>As more liquidity enters the Chinese banking system, it is expected that consumer confidence will rise, encouraging greater spending on luxury experiences and travel—a trend that benefits high-end resorts and casinos like those operated by Las Vegas Sands.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/markets/asia/24/09/41011343/tech-stocks-rise-materials-sector-rallies-on-chinas-stimulus-nvidia-surges-whats-driving-markets-tue">Tech Stocks Rise, Materials Sector Rallies On China&#8217;s Stimulus, Nvidia Surges: What&#8217;s Driving Markets Tuesday?</a></strong></p>
<h2 class="wp-block-heading">How To Buy LVS Stock</h2>
<p>Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. </p>
<p>For example, in Las Vegas Sands&#8217; case, it is in the Consumer Discretionary sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.</p>
<p>According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, LVS has a 52-week high of $55.66 and a 52-week low of $36.62.</p>


Las Vegas Sands (LVS) Stock Surges: Here's What's Fueling The Rally

<p>Shares of <strong>Biohaven Ltd.</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bhvn#NYSE">BHVN</a>) were up 13.7% on Sept. 23 after the company announced positive top-line data from the pivotal BHV4157-206-RWE study, which evaluated its pipeline candidate, troriluzole, for the treatment of spinocerebellar ataxia (SCA), a rare and debilitating neurodegenerative disease.</p>
<p>Currently, there are no FDA-approved therapy for the given indication.</p>
<p>The study showed the efficacy of troriluzole on the mean change from baseline in the modified functional Scale for the Assessment and Rating of Ataxia (f-SARA) following three years of treatment.</p>
<p>Year to date, shares of Biohaven have gained 7.4% with no change for the industry.</p>
<p><img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/ee/78970.jpg?v=729085404" /></p>
<p>Image Source: Zacks Investment Research</p>
<h2>BHVN&#39;s Pivotal BHV4157-206-RWE Study Data</h2>
<p>The study met the primary endpoint on the change from baseline in the f-SARA at three years in all study population genotypes following treatment with troriluzole (200 mg) in SCA patients.</p>
<p>Also, treatment with troriluzole led to statistically significant improvements in the f-SARA at years one and two. Data collected from multiple analyses showed a robust and clinically meaningful slowing of disease progression in SCA patients.</p>
<p>Importantly, treatment with troriluzole slowed disease progression by 50% to 70%, representing a 1.5-2.2 years delay in disease progression over three years compared to untreated patients.</p>
<p>Treatment with troriluzole demonstrated statistically significant superiority on nine consecutive, prespecified primary and secondary endpoints of the study.</p>
<p>Per management, troriluzole is the first treatment to show a delay in disease progression for SCA patients.</p>
<h2>BHVN&#39;s Upcoming Plans for Troriluzole</h2>
<p>Based on the positive data from the BHV4157-206-RWE study, along with previous safety and efficacy data, BHVN plans to submit a new drug application (NDA) for troriluzole in SCA with the FDA in the fourth quarter of 2024.</p>
<p>If approved, the company plans to launch troriluzole in the United States in 2025.</p>
<p>The FDA has granted Fast-Track and orphan drug designation to troriluzole for treating SCA. The European Medicines Agency has also granted orphan drug designation to troriluzole for treating SCA.</p>
<p>As a result of the orphan drug and fast-track designations granted by the FDA, the NDA for troriluzole is eligible for a priority review.</p>
<p>Troriluzole is also being evaluated in two late-stage studies for treating obsessive-compulsive disorder (OCD). Interim analysis of the second phase III OCD study is expected later in 2024, while top-line data from the first phase III OCD study is anticipated in the first half of 2025.</p>
<h2>Zacks Rank &amp; Stocks to Consider</h2>
<p>Biohaven currently carries a Zacks Rank #3 (Hold).</p>
<p>Some better-ranked stocks in the biotech sector are <strong>ANI Pharmaceuticals, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/anip#NASDAQ">ANIP</a>), <strong>Krystal Biotech, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/krys#NASDAQ">KRYS</a>) and <strong>Fulcrum Therapeutics, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fulc#NASDAQ">FULC</a>), each sporting a Zacks Rank #1 (Strong Buy) at present.</p>
<p>In the past 60 days, estimates for ANI Pharmaceuticals&#39; 2024 earnings per share have moved up from $4.49 to $4.82. Earnings per share estimates for 2025 have improved from $5.51 to $5.93. Year to date, shares of ANIP have gained 9%.</p>
<p>ANIP&#39;s earnings beat estimates in each of the trailing four quarters, with the average surprise being 31.32%.</p>
<p>In the past 60 days, estimates for Krystal Biotech&#39;s 2024 earnings per share have increased from $2.09 to $2.38. Earnings per share estimates for 2025 have improved from $4.33 to $7.31. Year to date, shares of KRYS have risen 45.3%.</p>
<p>KRYS&#39; earnings beat estimates in three of the trailing four quarters while missing on the remaining occasion, with the average surprise being 45.95%.</p>
<p>In the past 60 days, estimates for Fulcrum Therapeutics&#39; 2024 loss per share have narrowed from $1.33 to 28 cents. Loss per share estimates for 2025 have narrowed from $1.71 to $1.14. Year to date, shares of FULC have plunged 52.6%.</p>
<p>FULC&#39;s earnings beat estimates in each of the trailing four quarters, with the average surprise being 393.18%.</p>
<p><a href="https://www.zacks.com/stock/news/2340700/bhvn-stock-up-as-rare-neurological-disease-study-meets-primary-goal?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2340700">To read this article on Zacks.com click here.</a></p>


Biotech

Earnings

Earnings Beats

Mid Cap

Penny Stocks

Small Cap

Analyst Ratings

Trading Ideas

General

ANIP

BHVN

FULC

KRYS

BHVN Stock Up as Rare Neurological Disease Study Meets Primary Goal

<p><a href="https://x.com/ChristianWKRC/status/1838647038969319638" title="https://x.com/ChristianWKRC/status/1838647038969319638">https://x.com/ChristianWKRC/status/1838647038969319638</a></p>


Shares Of Norfolk Southern See Volume; WKRC-TV Journalist Post On X, 'An URGENT ALERT FROM THE @HCEMA IMMEDIATELY EVACUATE and leave area of US-50 and OH-128 in any direction due to chemical leak. Tune into @Local12 for more information.'

State Department Makes Determination Approving Sale To Egypt Of Stinger Missiles For $740M

<p>13 analysts have shared their evaluations of KeyCorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEY#NYSE">KEY</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $17.58, a high estimate of $20.00, and a low estimate of $15.00. This upward trend is evident, with the current average reflecting a 4.58% increase from the previous average price target of $16.81.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727204542_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>The perception of KeyCorp by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Chiaverini</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Neutral</td>
<td>$18.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>David Konrad</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$18.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Ken Usdin</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$19.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Manan Gosalia</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$20.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Gerard Cassidy</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$17.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Keith Horowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$19.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>David Chiaverini</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Neutral</td>
<td>$17.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Manan Gosalia</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$18.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Robert Kwan</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$17.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Peter Winter</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$18.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>David Chiaverini</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Neutral</td>
<td>$16.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Erika Najarian</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$15.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Steven Alexopoulos</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$16.50</td>
<td>$17.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to KeyCorp. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of KeyCorp compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into KeyCorp's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/KEY/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on KeyCorp analyst ratings.</strong></a></p>
<h2>All You Need to Know About KeyCorp</h2>
<p>With assets of over $180 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.</p>
<h3>KeyCorp's Financial Performance</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Negative Revenue Trend:</strong> Examining KeyCorp's financials over 3 months reveals challenges. As of 30 June, 2024, the company experienced a decline of approximately <strong>-4.46%</strong> in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>16.11%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> KeyCorp's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>1.96%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> KeyCorp's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>0.13%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> KeyCorp's debt-to-equity ratio surpasses industry norms, standing at <strong>1.8</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Navigating 13 Analyst Ratings For KeyCorp

<p>Generac Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNRC#NYSE">GNRC</a>) underwent analysis by 14 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $171.14, a high estimate of $200.00, and a low estimate of $148.00. Witnessing a positive shift, the current average has risen by 11.86% from the previous average price target of $153.00.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727204527_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>The standing of Generac Hldgs among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kashy Harrison</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$175.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Tommy Moll</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Jeffrey Osborne</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$172.00</td>
<td>$144.00</td>
</tr>
<tr>
<td>Jerry Revich</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$148.00</td>
<td>$129.00</td>
</tr>
<tr>
<td>Stephen Gengaro</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$175.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>George Gianarikas</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$200.00</td>
<td>$177.00</td>
</tr>
<tr>
<td>Praneeth Satish</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$156.00</td>
<td>$139.00</td>
</tr>
<tr>
<td>Michael Halloran</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$163.00</td>
<td>$142.00</td>
</tr>
<tr>
<td>Donovan Schafer</td>
<td>Northland Capital Markets</td>
<td>Raises</td>
<td>Outperform</td>
<td>$180.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Chip Moore</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Neutral</td>
<td>$160.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Tristan Richardson</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$160.00</td>
<td>$147.00</td>
</tr>
<tr>
<td>Kashy Harrison</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$175.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Mark Strouse</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$155.00</td>
<td>$149.00</td>
</tr>
<tr>
<td>George Gianarikas</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$177.00</td>
<td>$150.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Generac Hldgs. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Generac Hldgs compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Generac Hldgs's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Generac Hldgs's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/GNRC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Generac Hldgs analyst ratings.</strong></a></p>
<h2>Discovering Generac Hldgs: A Closer Look</h2>
<p>Generac designs and manufactures power generation equipment serving residential, commercial, and industrial markets. It offers standby generators, portable generators, lighting, outdoor power equipment, and a suite of clean energy products. Sales generated in the United States account for the majority of total sales.</p>
<h3>Unraveling the Financial Story of Generac Hldgs</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Challenges:</strong> Generac Hldgs's revenue growth over 3 months faced difficulties. As of 30 June, 2024, the company experienced a decline of approximately <strong>-0.22%</strong>. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> Generac Hldgs's net margin excels beyond industry benchmarks, reaching <strong>5.92%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Generac Hldgs's ROE excels beyond industry benchmarks, reaching <strong>2.5%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Generac Hldgs's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>1.15%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.72</strong>.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


GNRC

Analyst Expectations For Generac Hldgs's Future

<p>Comerica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMA#NYSE">CMA</a>) underwent analysis by 14 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $58.86, a high estimate of $75.00, and a low estimate of $50.00. Witnessing a positive shift, the current average has risen by 7.17% from the previous average price target of $54.92.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727204519_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>The standing of Comerica among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Chiaverini</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$75.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$66.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Terry McEvoy</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$58.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Peter Winter</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Christopher Mcgratty</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$69.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Manan Gosalia</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$61.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Manan Gosalia</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$50.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Jon Arfstrom</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$56.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Scott Siefers</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$52.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Jason Goldberg</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$56.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$53.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Christopher Mcgratty</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$56.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Michael Rose</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$60.00</td>
<td>-</td>
</tr>
<tr>
<td>Steven Alexopoulos</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$57.00</td>
<td>$62.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Comerica. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Comerica compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Comerica's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Comerica's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CMA/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Comerica analyst ratings.</strong></a></p>
<h2>Delving into Comerica's Background</h2>
<p>Comerica is a financial services company headquartered in Dallas. It is primarily focused on relationship-based commercial banking. In addition to Texas, Comerica's other primary geographies are California and Michigan, with locations also in Arizona and Florida and select businesses operating in several other states as well as Canada and Mexico.</p>
<h3>Comerica's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Comerica's revenue growth over a period of 3 months has faced challenges. As of 30 June, 2024, the company experienced a revenue decline of approximately <strong>-10.82%</strong>. This indicates a decrease in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Comerica's net margin is impressive, surpassing industry averages. With a net margin of <strong>24.27%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Comerica's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>3.5%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Comerica's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>0.25%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Comerica's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>1.45</strong>.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


What 14 Analyst Ratings Have To Say About Comerica

<p>In the preceding three months, 14 analysts have released ratings for Texas Roadhouse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXRH#NASDAQ">TXRH</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $183.93, a high estimate of $205.00, and a low estimate of $155.00. This current average has increased by 4.38% from the previous average price target of $176.21. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727204487_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>The standing of Texas Roadhouse among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nick Setyan</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$190.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>John Ivankoe</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$180.00</td>
<td>$184.00</td>
</tr>
<tr>
<td>Jim Salera</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$176.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Peter Saleh</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>David Palmer</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$195.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Andrew Strelzik</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$155.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Jake Bartlett</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$196.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Jon Tower</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$175.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Nick Setyan</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$190.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Sara Senatore</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$205.00</td>
<td>$189.00</td>
</tr>
<tr>
<td>John Glass</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$162.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Brian Mullen</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$193.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Jake Bartlett</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$185.00</td>
<td>$183.00</td>
</tr>
<tr>
<td>Jake Bartlett</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$183.00</td>
<td>$181.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Texas Roadhouse. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Texas Roadhouse compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Texas Roadhouse's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Texas Roadhouse's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TXRH/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Texas Roadhouse analyst ratings.</strong></a></p>
<h2>About Texas Roadhouse</h2>
<p>Texas Roadhouse Inc is a restaurant company operating predominately in the casual dining segment. The company's operating segment includes Texas Roadhouse; Bubba's 33 and others. It generates maximum revenue from the Texas Roadhouse segment.</p>
<h3>Financial Insights: Texas Roadhouse</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Texas Roadhouse showcased positive performance, achieving a revenue growth rate of <strong>14.51%</strong> as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Texas Roadhouse's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>8.96%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Texas Roadhouse's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>9.73%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Texas Roadhouse's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>4.22%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Texas Roadhouse's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.64</strong>.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


TXRH

The Analyst Landscape: 14 Takes On Texas Roadhouse

<p>Over the past 24 hours, <strong>Aave's</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/aave/usd">AAVE</a>) price has fallen 6.91% to <strong>$164.69</strong>. This is opposite to its positive trend over the past week where it has experienced a 16.0% gain, moving from $142.23 to its current price. </p>
<p>The chart below compares the price movement and volatility for Aave over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727204475_0.png" alt="price_chart" /></p>
<p><strong>The trading volume for the coin has increased 26.0%</strong> over the past week while the overall circulating supply of the coin has increased 0.09% to over 14.94 million which makes up an estimated 93.36% of its max supply, which is 16.00 million. The current market cap ranking for <strong>AAVE</strong> is <strong>#42</strong> at <strong>$2.46 billion</strong>.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727204475_1.png" alt="supply_and_vol" /></p>
<p><a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Movers

$AAVE

Cryptocurrency Aave Down More Than 6% Within 24 hours

<p>Aerospace company <strong>Boeing Co</strong> (NYSE) has endured a tumultuous 2024, grappling with airplane safety concerns, astronauts stranded in space, and serious contract disputes <a href="https://www.benzinga.com/general/24/09/40996898/boeings-striking-workers-reject-best-and-final-offer-it-missed-the-mark-on-many-of-the-things">with union workers.</a></p>
<p>The company's battle with SpaceX over space contracts may face significant challenges in the coming months and years due to these recent setbacks.</p>
<p><strong>What Happened: </strong>Boeing is currently facing a battle with union workers over contract demands<span style="box-sizing: border-box; margin: 0px; padding: 0px;">, as over 30,000 employees have gone on strike. As a result of the contract disputes, the company has also <a href="https://www.benzinga.com/news/24/09/40886979/boeing-stock-continues-to-fall-after-announcing-hiring-freeze-other-cost-cuts-amid-workers-strike" target="_blank" rel="noopener">placed a freeze on hiring </a>and considered furloughs</span>.</p>
<p>The labor battle compounds the company's recent troubles and could provide fuel for rival SpaceX and its CEO <strong>Elon Musk</strong> in future contracts with space agencies like NASA.</p>
<p>SpaceX has been dominating the space sector for many years and its recently complete space walk could lead to the company landing more deals, especially considering the concerns facing Boeing and its space division.</p>
<p>After several delays, Boeing sent the Starliner to the International Space Station (ISS) on June 5. <span style="box-sizing: border-box; margin: 0px; padding: 0px;">The Starliner was supposed to return astronauts <strong>Butch Wilmore </strong>and <strong>Suni Williams </strong>to Earth on June 14, </span>but the duo remains stuck on the ISS due to complications with the spacecraft.</p>
<p>Ironically, it will be SpaceX that brings <a href="https://www.benzinga.com/news/24/08/40594834/spacex-ceo-elon-musk-takes-another-dig-at-boeing-for-failing-to-return-astronauts-on-starliner-ride">the astronauts home </a>next year aboard a SpaceX Dragon capsule.</p>
<p>Musk has often criticized Boeing and other companies that have won larger contracts than SpaceX, despite his space company's leadership and success in the sector.</p>
<p>"Our Dragon spacecraft is the only spacecraft capable of taking any significant cargo down from the Space Station," Musk <a href="https://www.benzinga.com/news/24/09/40899599/elon-musk-said-spacex-competitors-only-take-up-less-than-we-do-and-they-take-nothing-down-and-they-g">said back in 2014.</a> "They only take stuff up, they take up less than we do, and they take nothing down, and they get paid twice as much per mission as we do."</p>
<p>The Dragon <a href="https://www.benzinga.com/general/space/24/04/38297698/boeing-heads-to-space-could-nasa-deal-starliner-help-fend-off-airplane-segment-weakness">landed a $2.6 billion contract</a> in 2014 and has made multiple trips to the International Space Station. Boeing was awarded a similar contract in 2014 for ISS travel and the Starliner, but with a higher value of more than $4 billion. The June mission was Boeing's first to the Space Station.</p>
<p>Boeing&#8217;s safety concerns, Starliner struggles, and potential labor disruptions from union negotiations may all be factors that NASA and other organizations consider when awarding future contracts. Compare that to SpaceX, which has had successful missions, and Musk's well-known anti-union beliefs, resulting in fewer wage-related issues at his companies over the years.</p>
<p><strong>Did You Know?</strong></p>
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent092424"><strong>Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</strong></a></li>
</ul>
<p><strong>Why It's Important</strong>: Safety and costs will likely be top priorities for a government agency like NASA when considering a contract winner.</p>
<p>Musk has recently accused the Federal Aviation Administration (FAA) <a href="https://www.benzinga.com/markets/equities/24/09/40912464/elon-musk-accuses-faa-of-fining-spacex-over-nonsense-that-doesnt-affect-safety-amazingly-no-star">of favoritism towards </a>Boeing as the agency weighs a potential fine on SpaceX. Musk questions why Boeing has not faced fines or pushback over the Starliner stranding two people in space.</p>
<p>Boeing's Defense, Space &amp; Security segment had revenue of $25 billion in 2023 and was its second-largest segment, behind commercial airplanes ($33.9 billion).</p>
<p>For Boeing investors, there could be concerns across multiple divisions as new leadership looks to turn around the commercial airplanes segment after safety concerns and government inquiries. The space segment could also see setbacks thanks in part to its own doing, and also the success of its rival.</p>
<p><strong>BA Price Action</strong>: Boeing stock trades at $154.99 versus a 52-week trading range of $151.65 to $267.54. Boeing stock is down 38% year-to-date in 2024.</p>
<p><strong>Read Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/general/space/24/09/40842633/public-company-ceo-goes-to-space-is-there-risk-for-shareholders-when-billionaires-pursue-space-drea">Public Company CEO Goes To Space: Is There Risk For Shareholders When Billionaires Pursue Space Dreams?</a></strong></li>
</ul>
<p><em>Photo: Shutterstock</em></p>


SPACE

Tech

Boeing Vs. SpaceX: Will Stumbles In Union Negotiations, Space Travel Weaken Aerospace Giant's Standing Against Elon Musk's Company?

European Aeronautic Defence And Space Unsponsored

EADSY

Hawaiian Airlines Now Offering Fast And Free Starlink Wi-Fi Across Entire Airbus Fleet

<p>Financial giants have made a conspicuous bearish move on Biomarin Pharmaceutical. Our analysis of options history for Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) revealed 9 unusual trades.</p>
<p>Delving into the details, we found 33% of traders were bullish, while 55% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $101,040, and 6 were calls, valued at $384,540.</p>
<h3>What's The Price Target?</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $65.0 to $90.0 for Biomarin Pharmaceutical over the last 3 months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>In terms of liquidity and interest, the mean open interest for Biomarin Pharmaceutical options trades today is 583.17 with a total volume of 8,431.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Biomarin Pharmaceutical's big money trades within a strike price range of $65.0 to $90.0 over the last 30 days.</p>
<h3>Biomarin Pharmaceutical Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727204455_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>BMRN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$5.9</td>
<td>$5.7</td>
<td>$5.7</td>
<td>$67.50</td>
<td>$114.0K</td>
<td>0</td>
<td>200</td>
</tr>
<tr>
<td>BMRN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$4.6</td>
<td>$4.1</td>
<td>$4.4</td>
<td>$70.00</td>
<td>$88.0K</td>
<td>864</td>
<td>300</td>
</tr>
<tr>
<td>BMRN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$0.4</td>
<td>$0.25</td>
<td>$0.35</td>
<td>$90.00</td>
<td>$77.4K</td>
<td>930</td>
<td>3.0K</td>
</tr>
<tr>
<td>BMRN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$4.6</td>
<td>$4.4</td>
<td>$4.55</td>
<td>$70.00</td>
<td>$45.1K</td>
<td>864</td>
<td>100</td>
</tr>
<tr>
<td>BMRN</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$11.6</td>
<td>$11.2</td>
<td>$11.4</td>
<td>$80.00</td>
<td>$41.0K</td>
<td>1.2K</td>
<td>0</td>
</tr>
</tbody>
</table>
</p>
<h3>About Biomarin Pharmaceutical</h3>
<p>BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.</p>
<h3>Current Position of Biomarin Pharmaceutical</h3>
<ul>
<li>Trading volume stands at 1,372,747, with BMRN's price down by -0.2%, positioned at $68.99.</li>
<li>RSI indicators show the stock to be may be oversold.</li>
<li>Earnings announcement expected in 36 days.</li>
</ul>
<h3>What The Experts Say On Biomarin Pharmaceutical</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $109.8.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Piper Sandler continues to hold a Overweight rating for Biomarin Pharmaceutical, targeting a price of $107.<br />
&#x2A; Consistent in their evaluation, an analyst from Piper Sandler keeps a Overweight rating on Biomarin Pharmaceutical with a target price of $122.<br />
&#x2A; An analyst from Bernstein persists with their Outperform rating on Biomarin Pharmaceutical, maintaining a target price of $90.<br />
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $110.<br />
&#x2A; An analyst from JP Morgan persists with their Overweight rating on Biomarin Pharmaceutical, maintaining a target price of $120. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Biomarin Pharmaceutical with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Options

BMRN

Biomarin Pharmaceutical Options Trading: A Deep Dive into Market Sentiment

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Beyond Meat</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYND#NASDAQ">BYND</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether this is an institution or just a wealthy individual, we don't know. But when something this big happens with BYND, it often means somebody knows something is about to happen.</p>
<p>Today, Benzinga's options scanner spotted 10 options trades for Beyond Meat.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 80% bullish and 10%, bearish.</p>
<p>Out of all of the options we uncovered, 9 are puts, for a total amount of $694,658, and there was 1 call, for a total amount of $57,000.</p>
<h3>What's The Price Target?</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $5.0 to $11.0 for Beyond Meat over the recent three months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Beyond Meat's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Beyond Meat's whale activity within a strike price range from $5.0 to $11.0 in the last 30 days. </p>
<h3>Beyond Meat Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727204450_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>BYND</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$4.7</td>
<td>$4.6</td>
<td>$4.63</td>
<td>$11.00</td>
<td>$157.5K</td>
<td>552</td>
<td>1.0K</td>
</tr>
<tr>
<td>BYND</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$2.24</td>
<td>$1.8</td>
<td>$1.8</td>
<td>$6.00</td>
<td>$108.0K</td>
<td>5.9K</td>
<td>600</td>
</tr>
<tr>
<td>BYND</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>10/18/24</td>
<td>$4.7</td>
<td>$4.65</td>
<td>$4.67</td>
<td>$11.00</td>
<td>$93.5K</td>
<td>552</td>
<td>436</td>
</tr>
<tr>
<td>BYND</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$4.6</td>
<td>$4.45</td>
<td>$4.49</td>
<td>$11.00</td>
<td>$71.8K</td>
<td>552</td>
<td>1.1K</td>
</tr>
<tr>
<td>BYND</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$4.9</td>
<td>$4.6</td>
<td>$4.63</td>
<td>$11.00</td>
<td>$67.1K</td>
<td>552</td>
<td>581</td>
</tr>
</tbody>
</table>
</p>
<h3>About Beyond Meat</h3>
<p>Beyond Meat Inc is a provider of plant-based meat company offering a portfolio of revolutionary plant-based meats. It builds meat directly from plants, an innovation that enables consumers to experience the taste, texture and other sensory attributes of popular animal-based meat products while enjoying the nutritional and environmental benefits of eating plant-based meat product It has products such as burgers, sausage, ground beef, jerky, meatballs and chicken. The company generates revenue from sales of its products to the customers across mainstream grocery, mass merchandiser, club store, convenience store and natural retailer channels, and various food-away-from-home channels, including restaurants, foodservice outlets and schools, mainly in the United States.</p>
<p>Following our analysis of the options activities associated with Beyond Meat, we pivot to a closer look at the company's own performance.</p>
<h3>Present Market Standing of Beyond Meat</h3>
<ul>
<li>Trading volume stands at 1,560,170, with BYND's price up by 5.34%, positioned at $6.71.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 43 days.</li>
</ul>
<h3>Expert Opinions on Beyond Meat</h3>
<p>In the last month, 1 experts released ratings on this stock with an average target price of $5.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Mizuho has decided to maintain their Underperform rating on Beyond Meat, which currently sits at a price target of $5. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Beyond Meat, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


BYND

Market Whales and Their Recent Bets on BYND Options

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>CVS Health</strong>.</p>
<p>Looking at options history for CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) we detected 9 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 55% of the investors opened trades with bullish expectations and 33% with bearish.</p>
<p>From the overall spotted trades, 3 are puts, for a total amount of $1,133,806 and 6, calls, for a total amount of $548,539.</p>
<h3>Expected Price Movements</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $45.0 to $62.5 for CVS Health during the past quarter. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for CVS Health's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of CVS Health's whale activity within a strike price range from $45.0 to $62.5 in the last 30 days. </p>
<h3>CVS Health Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727204445_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$7.1</td>
<td>$6.95</td>
<td>$6.96</td>
<td>$62.50</td>
<td>$1.0M</td>
<td>4.3K</td>
<td>1.6K</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/18/26</td>
<td>$17.15</td>
<td>$15.1</td>
<td>$16.5</td>
<td>$45.00</td>
<td>$163.3K</td>
<td>593</td>
<td>100</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/11/24</td>
<td>$1.82</td>
<td>$1.64</td>
<td>$1.84</td>
<td>$58.00</td>
<td>$119.3K</td>
<td>88</td>
<td>1.0K</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$9.55</td>
<td>$9.45</td>
<td>$9.45</td>
<td>$50.00</td>
<td>$99.2K</td>
<td>1.2K</td>
<td>115</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$3.6</td>
<td>$3.45</td>
<td>$3.6</td>
<td>$60.00</td>
<td>$77.3K</td>
<td>10.0K</td>
<td>251</td>
</tr>
</tbody>
</table>
</p>
<h3>About CVS Health</h3>
<p>CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the us. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 26 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all its existing business lines.</p>
<h3>Present Market Standing of CVS Health</h3>
<ul>
<li>Currently trading with a volume of 3,408,776, the CVS's price is up by 0.56%, now at $57.89. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 43 days.</li>
</ul>
<h3>What Analysts Are Saying About CVS Health</h3>
<p>3 market experts have recently issued ratings for this stock, with a consensus target price of $64.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from RBC Capital downgraded its action to Outperform with a price target of $68.<br />
&#x2A; An analyst from Cantor Fitzgerald downgraded its action to Neutral with a price target of $62.<br />
&#x2A; An analyst from Cantor Fitzgerald downgraded its action to Neutral with a price target of $62. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for CVS Health, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


CVS Health's Options: A Look at What the Big Money is Thinking

<p>During the last three months, 12 analysts shared their evaluations of Reinsurance Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RGA#NYSE">RGA</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $221.5, a high estimate of $255.00, and a low estimate of $64.00. Witnessing a positive shift, the current average has risen by 7.29% from the previous average price target of $206.45.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727204428_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Reinsurance Gr. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wilma Burdis</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$250.00</td>
<td>$228.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$255.00</td>
<td>-</td>
</tr>
<tr>
<td>Nigel Dally</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$236.00</td>
<td>$238.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$239.00</td>
<td>$236.00</td>
</tr>
<tr>
<td>Mark Dwelle</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$235.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Jimmy Bhullar</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$220.00</td>
<td>$208.00</td>
</tr>
<tr>
<td>Michael Ward</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$252.00</td>
<td>$194.00</td>
</tr>
<tr>
<td>Suneet Kamath</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$64.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Nigel Dally</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$217.00</td>
<td>$216.00</td>
</tr>
<tr>
<td>Jimmy Bhullar</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$208.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Suneet Kamath</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$247.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>John Barnidge</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$235.00</td>
<td>$228.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Reinsurance Gr. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Reinsurance Gr compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Reinsurance Gr's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>For valuable insights into Reinsurance Gr's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/RGA/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Reinsurance Gr analyst ratings.</strong></a></p>
<h2>Delving into Reinsurance Gr's Background</h2>
<p>Reinsurance Group of America Inc is an insurance holding company with operations in the United States, Latin America, Canada, Europe, Africa, Asia, and Australia. The core products and services include life reinsurance, living benefits reinsurance, group reinsurance, health reinsurance, financial solutions, facultative underwriting, and product development. The company's operations are divided into traditional and financial solution businesses.</p>
<h3>Financial Milestones: Reinsurance Gr's Journey</h3>
<p><strong>Market Capitalization:</strong> Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Reinsurance Gr's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>17.4%</strong> as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> Reinsurance Gr's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>4.18%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Reinsurance Gr's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>2.11%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Reinsurance Gr's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>0.19%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Reinsurance Gr's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>0.52</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Cracking The Code: Understanding Analyst Reviews For Reinsurance Gr

<p>Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) has outperformed the market over the past 15 years by 10.71% on an annualized basis producing an average annual return of 22.61%. Currently, Insulet has a market capitalization of $16.75 billion. </p>
<p><strong>Buying $100 In PODD:</strong> If an investor had bought $100 of PODD stock 15 years ago, it would be worth <strong>$2,138.90</strong> today based on a price of $238.91 for PODD at the time of writing.</p>
<h3>Insulet's Performance Over Last 15 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727204416_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


PODD

Here's How Much $100 Invested In Insulet 15 Years Ago Would Be Worth Today

<p>Vertiv Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>) has outperformed the market over the past 5 years by 43.04% on an annualized basis producing an average annual return of 57.01%. Currently, Vertiv Hldgs has a market capitalization of $36.51 billion. </p>
<p><strong>Buying $100 In VRT:</strong> If an investor had bought $100 of VRT stock 5 years ago, it would be worth <strong>$947.61</strong> today based on a price of $97.32 for VRT at the time of writing.</p>
<h3>Vertiv Hldgs's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727204410_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


$100 Invested In This Stock 5 Years Ago Would Be Worth $900 Today

<p>Analysts' ratings for Corteva (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTVA#NYSE">CTVA</a>) over the last quarter vary from bullish to bearish, as provided by 4 analysts.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Corteva, revealing an average target of $61.75, a high estimate of $65.00, and a low estimate of $55.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 3.14%. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727204409_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>A comprehensive examination of how financial experts perceive Corteva is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vincent Andrews</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$65.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Jeffrey Zekauskas</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$55.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Richard Garchitorena</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$65.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Aleksey Yefremov</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$62.00</td>
<td>$66.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Corteva. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Corteva compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Corteva's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Corteva's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CTVA/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Corteva analyst ratings.</strong></a></p>
<h2>Delving into Corteva's Background</h2>
<p>Corteva is an agricultural inputs pure play that was formed in 2019 when it was spun off from DowDuPont. The company is a leader in the development of new seed and crop protection products. Seeds generate the majority of profits with the remainder coming from crop protection products. Corteva operates globally, but around half of revenue comes from North America.</p>
<h3>Financial Insights: Corteva</h3>
<p><strong>Market Capitalization Highlights:</strong> Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.</p>
<p><strong>Revenue Growth:</strong> Corteva's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately <strong>1.11%</strong>. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Materials sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>17.23%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>4.22%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Corteva's ROA excels beyond industry benchmarks, reaching <strong>2.48%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Corteva's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.19</strong>.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CTVA

Critical Insights From Corteva Analyst Ratings: What You Need To Know

<p><strong>Stacks's</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/stx/usd">STX</a>) price has increased 5.35% over the past 24 hours to <strong>$1.94</strong>. Over the past week, STX has experienced an uptick of over 25.0%, moving from $1.54 to its current price.  As it stands right now, <strong>the coin's all-time high is $3.86</strong>. </p>
<p>The chart below compares the price movement and volatility for Stacks over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727204406_0.png" alt="price_chart" /></p>
<p><strong>The trading volume for the coin has increased 240.0%</strong> over the past week while the overall circulating supply of the coin has increased 0.26% to over 1.49 billion which makes up an estimated 81.99% of its max supply, which is 1.82 billion. The current market cap ranking for <strong>STX</strong> is <strong>#37</strong> at <strong>$2.89 billion</strong>.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727204406_1.png" alt="supply_and_vol" /></p>
<p><a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

iShares Core MSCI Europe ETF

Overview

iShares Core MSCI Europe ETF (ARCA:IEUR), Quote.Headers.trade-ideas